Oxford BioDynamics launches its Checkpoint Inhibitor response test in the US
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
Study to evaluate effectiveness of hypoglossal nerve stimulation
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
Guy Villax was also involved with the EFCG and Rx-360 associations and contributed to legislation being passed on both sides of the Atlantic to fight fake medicines and to level the playing field for GMP manufacturing.
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
The facility is spread across 215000 sq. feet and provides super-speciality care
This policy will ensure multi-disciplinary collaboration, promote start-up culture and develop an innovation-led ecosystem at medical institutes across the country
The joint initiative is called J-ARC Healthcare Solutions
Subscribe To Our Newsletter & Stay Updated